BMSC550 Pharmacology Exam Prep – Real Practice Questions, Answers
& Detailed Rationales (Updated 2026) | Drug Classes &
Mechanisms of Action, Pharmacokinetics & Pharmacodynamics, Receptor
Binding, Drug Interactions & Contraindications, Side Effects & Adverse
Reactions, Toxicology, Dosage Calculations, Medication Safety, Clinical
Pharmacology Applications
Question 1: Which of the following best describes the term "bioavailability" in
pharmacokinetics?
A. The rate at which a drug is eliminated from the body
B. The fraction of an administered dose that reaches systemic circulation unchanged
C. The volume of plasma required to contain the total amount of drug in the body
D. The time required for a drug to reach its peak plasma concentration
CORRECT ANSWER: B. The fraction of an administered dose that reaches systemic
circulation unchanged
Rationale: Bioavailability (F) quantifies the proportion of an administered drug dose that
enters systemic circulation in its active, unchanged form. It is a critical parameter for
comparing different routes of administration and formulations. Intravenous
administration has 100% bioavailability by definition, while oral drugs often have lower
values due to incomplete absorption and first-pass metabolism.
Question 2: A drug with a high volume of distribution (Vd) is most likely to:
A. Be confined primarily to the plasma compartment
B. Have limited tissue penetration and remain in the bloodstream
C. Distribute extensively into tissues and have low plasma concentrations
D. Be rapidly eliminated by renal excretion
CORRECT ANSWER: C. Distribute extensively into tissues and have low plasma
concentrations
Rationale: Volume of distribution (Vd) is a theoretical parameter reflecting the apparent
space in the body available to contain the drug. A high Vd indicates extensive
distribution into tissues beyond plasma, often due to high lipid solubility, tissue binding,
or sequestration. This results in relatively low plasma concentrations relative to the
total amount of drug in the body.
Question 3: Which pharmacodynamic concept describes the maximum effect a
drug can produce regardless of dose?
A. Potency
B. Affinity
C. Efficacy
D. Therapeutic index
CORRECT ANSWER: C. Efficacy
,Rationale: Efficacy (Emax) refers to the maximum biological response a drug can elicit,
representing its intrinsic ability to activate receptors and produce a response once
bound. Potency relates to the dose required to produce a given effect, affinity describes
binding strength to receptors, and therapeutic index is a measure of drug safety.
Question 4: In competitive antagonism, the presence of an antagonist typically
causes:
A. A decrease in the maximal response achievable by the agonist
B. A rightward shift of the agonist dose-response curve without reducing Emax
C. An increase in the agonist's affinity for its receptor
D. Irreversible blockade of the receptor binding site
CORRECT ANSWER: B. A rightward shift of the agonist dose-response curve without
reducing Emax
Rationale: Competitive antagonists bind reversibly to the same site as the agonist,
competing for occupancy. This increases the concentration of agonist needed to
achieve a given effect (rightward shift), but sufficient agonist can still overcome the
blockade to achieve the original maximal response (Emax unchanged). Non-
competitive antagonism reduces Emax.
Question 5: Which enzyme system is primarily responsible for Phase I metabolism
of most drugs in the liver?
A. UDP-glucuronosyltransferases
B. Cytochrome P450 monooxygenases
C. Glutathione S-transferases
D. N-acetyltransferases
CORRECT ANSWER: B. Cytochrome P450 monooxygenases
Rationale: The cytochrome P450 (CYP) superfamily, particularly CYP3A4, CYP2D6, and
CYP2C9, catalyzes the majority of Phase I reactions (oxidation, reduction, hydrolysis)
that introduce or expose functional groups on drugs. Phase II enzymes like UDP-
glucuronosyltransferases conjugate these metabolites for excretion.
Question 6: A patient taking warfarin develops excessive anticoagulation after
starting a new medication. Which mechanism is MOST likely responsible if the new
drug inhibits CYP2C9?
A. Increased renal excretion of warfarin
B. Decreased protein binding of warfarin
C. Reduced metabolic clearance of warfarin
D. Enhanced intestinal absorption of warfarin
CORRECT ANSWER: C. Reduced metabolic clearance of warfarin
Rationale: Warfarin is primarily metabolized by CYP2C9. Inhibition of this enzyme
decreases warfarin's metabolic clearance, leading to elevated plasma concentrations,
,prolonged half-life, and increased anticoagulant effect. This is a classic
pharmacokinetic drug-drug interaction with significant clinical consequences.
Question 7: Which statement best characterizes a drug with a narrow therapeutic
index?
A. It has a large difference between effective and toxic doses
B. It requires frequent monitoring of plasma concentrations to ensure safety
C. It is unlikely to cause adverse effects at standard doses
D. It has high bioavailability across different patient populations
CORRECT ANSWER: B. It requires frequent monitoring of plasma concentrations to
ensure safety
Rationale: Drugs with a narrow therapeutic index (NTI) have a small margin between
therapeutic and toxic concentrations (e.g., digoxin, lithium, warfarin). Small changes in
dose or clearance can lead to toxicity or therapeutic failure, necessitating therapeutic
drug monitoring (TDM) to optimize dosing.
Question 8: The autonomic nervous system drug that acts as a selective β1-
adrenergic receptor antagonist is:
A. Propranolol
B. Atenolol
C. Prazosin
D. Clonidine
CORRECT ANSWER: B. Atenolol
Rationale: Atenolol is a cardioselective β1-adrenergic receptor blocker used for
hypertension and angina. Propranolol is non-selective (β1 and β2), prazosin is an α1-
adrenergic antagonist, and clonidine is a central α2-adrenergic agonist. Selectivity
reduces risk of bronchoconstriction in patients with respiratory conditions.
Question 9: Which cholinergic agonist is most appropriate for treating acute angle-
closure glaucoma due to its rapid miotic effect?
A. Bethanechol
B. Pilocarpine
C. Neostigmine
D. Donepezil
CORRECT ANSWER: B. Pilocarpine
Rationale: Pilocarpine is a direct-acting muscarinic agonist that causes pupillary
constriction (miosis) and ciliary muscle contraction, facilitating aqueous humor outflow
and reducing intraocular pressure in acute angle-closure glaucoma. Bethanechol
targets bladder/GI tract, neostigmine is an indirect cholinesterase inhibitor, and
donepezil is used for Alzheimer's disease.
, Question 10: Organophosphate poisoning is treated with pralidoxime (2-PAM)
primarily because it:
A. Blocks muscarinic receptors to reduce secretions
B. Reactivates acetylcholinesterase inhibited by organophosphates
C. Enhances renal excretion of the toxin
D. Stimulates nicotinic receptors to restore neuromuscular function
CORRECT ANSWER: B. Reactivates acetylcholinesterase inhibited by
organophosphates
Rationale: Organophosphates irreversibly phosphorylate acetylcholinesterase.
Pralidoxime is an oxime that nucleophilically attacks the phosphorylated enzyme,
regenerating active acetylcholinesterase if administered before "aging" occurs. Atropine
is co-administered to block excess muscarinic stimulation.
Question 11: Which calcium channel blocker is most selective for vascular smooth
muscle and is preferred for hypertension?
A. Verapamil
B. Diltiazem
C. Nifedipine
D. Bepridil
CORRECT ANSWER: C. Nifedipine
Rationale: Dihydropyridines like nifedipine exhibit high selectivity for L-type calcium
channels in vascular smooth muscle over cardiac tissue, causing potent vasodilation
with minimal negative inotropy. Verapamil and diltiazem have greater cardiac effects
and are used for arrhythmias or angina.
Question 12: The primary mechanism by which ACE inhibitors reduce blood
pressure is:
A. Blockade of angiotensin II type 1 (AT1) receptors
B. Inhibition of angiotensin-converting enzyme, reducing angiotensin II formation
C. Direct vasodilation via nitric oxide release
D. Increased renal excretion of sodium and water
CORRECT ANSWER: B. Inhibition of angiotensin-converting enzyme, reducing
angiotensin II formation
Rationale: ACE inhibitors (e.g., lisinopril) block conversion of angiotensin I to
angiotensin II, a potent vasoconstrictor and aldosterone stimulator. This reduces
vascular tone, blood volume, and cardiac remodeling. ARBs (option A) block the
receptor directly; diuretics cause option D.
Question 13: Which antiarrhythmic drug class is characterized by sodium channel
blockade with slow kinetics, prolonging the QRS complex?
& Detailed Rationales (Updated 2026) | Drug Classes &
Mechanisms of Action, Pharmacokinetics & Pharmacodynamics, Receptor
Binding, Drug Interactions & Contraindications, Side Effects & Adverse
Reactions, Toxicology, Dosage Calculations, Medication Safety, Clinical
Pharmacology Applications
Question 1: Which of the following best describes the term "bioavailability" in
pharmacokinetics?
A. The rate at which a drug is eliminated from the body
B. The fraction of an administered dose that reaches systemic circulation unchanged
C. The volume of plasma required to contain the total amount of drug in the body
D. The time required for a drug to reach its peak plasma concentration
CORRECT ANSWER: B. The fraction of an administered dose that reaches systemic
circulation unchanged
Rationale: Bioavailability (F) quantifies the proportion of an administered drug dose that
enters systemic circulation in its active, unchanged form. It is a critical parameter for
comparing different routes of administration and formulations. Intravenous
administration has 100% bioavailability by definition, while oral drugs often have lower
values due to incomplete absorption and first-pass metabolism.
Question 2: A drug with a high volume of distribution (Vd) is most likely to:
A. Be confined primarily to the plasma compartment
B. Have limited tissue penetration and remain in the bloodstream
C. Distribute extensively into tissues and have low plasma concentrations
D. Be rapidly eliminated by renal excretion
CORRECT ANSWER: C. Distribute extensively into tissues and have low plasma
concentrations
Rationale: Volume of distribution (Vd) is a theoretical parameter reflecting the apparent
space in the body available to contain the drug. A high Vd indicates extensive
distribution into tissues beyond plasma, often due to high lipid solubility, tissue binding,
or sequestration. This results in relatively low plasma concentrations relative to the
total amount of drug in the body.
Question 3: Which pharmacodynamic concept describes the maximum effect a
drug can produce regardless of dose?
A. Potency
B. Affinity
C. Efficacy
D. Therapeutic index
CORRECT ANSWER: C. Efficacy
,Rationale: Efficacy (Emax) refers to the maximum biological response a drug can elicit,
representing its intrinsic ability to activate receptors and produce a response once
bound. Potency relates to the dose required to produce a given effect, affinity describes
binding strength to receptors, and therapeutic index is a measure of drug safety.
Question 4: In competitive antagonism, the presence of an antagonist typically
causes:
A. A decrease in the maximal response achievable by the agonist
B. A rightward shift of the agonist dose-response curve without reducing Emax
C. An increase in the agonist's affinity for its receptor
D. Irreversible blockade of the receptor binding site
CORRECT ANSWER: B. A rightward shift of the agonist dose-response curve without
reducing Emax
Rationale: Competitive antagonists bind reversibly to the same site as the agonist,
competing for occupancy. This increases the concentration of agonist needed to
achieve a given effect (rightward shift), but sufficient agonist can still overcome the
blockade to achieve the original maximal response (Emax unchanged). Non-
competitive antagonism reduces Emax.
Question 5: Which enzyme system is primarily responsible for Phase I metabolism
of most drugs in the liver?
A. UDP-glucuronosyltransferases
B. Cytochrome P450 monooxygenases
C. Glutathione S-transferases
D. N-acetyltransferases
CORRECT ANSWER: B. Cytochrome P450 monooxygenases
Rationale: The cytochrome P450 (CYP) superfamily, particularly CYP3A4, CYP2D6, and
CYP2C9, catalyzes the majority of Phase I reactions (oxidation, reduction, hydrolysis)
that introduce or expose functional groups on drugs. Phase II enzymes like UDP-
glucuronosyltransferases conjugate these metabolites for excretion.
Question 6: A patient taking warfarin develops excessive anticoagulation after
starting a new medication. Which mechanism is MOST likely responsible if the new
drug inhibits CYP2C9?
A. Increased renal excretion of warfarin
B. Decreased protein binding of warfarin
C. Reduced metabolic clearance of warfarin
D. Enhanced intestinal absorption of warfarin
CORRECT ANSWER: C. Reduced metabolic clearance of warfarin
Rationale: Warfarin is primarily metabolized by CYP2C9. Inhibition of this enzyme
decreases warfarin's metabolic clearance, leading to elevated plasma concentrations,
,prolonged half-life, and increased anticoagulant effect. This is a classic
pharmacokinetic drug-drug interaction with significant clinical consequences.
Question 7: Which statement best characterizes a drug with a narrow therapeutic
index?
A. It has a large difference between effective and toxic doses
B. It requires frequent monitoring of plasma concentrations to ensure safety
C. It is unlikely to cause adverse effects at standard doses
D. It has high bioavailability across different patient populations
CORRECT ANSWER: B. It requires frequent monitoring of plasma concentrations to
ensure safety
Rationale: Drugs with a narrow therapeutic index (NTI) have a small margin between
therapeutic and toxic concentrations (e.g., digoxin, lithium, warfarin). Small changes in
dose or clearance can lead to toxicity or therapeutic failure, necessitating therapeutic
drug monitoring (TDM) to optimize dosing.
Question 8: The autonomic nervous system drug that acts as a selective β1-
adrenergic receptor antagonist is:
A. Propranolol
B. Atenolol
C. Prazosin
D. Clonidine
CORRECT ANSWER: B. Atenolol
Rationale: Atenolol is a cardioselective β1-adrenergic receptor blocker used for
hypertension and angina. Propranolol is non-selective (β1 and β2), prazosin is an α1-
adrenergic antagonist, and clonidine is a central α2-adrenergic agonist. Selectivity
reduces risk of bronchoconstriction in patients with respiratory conditions.
Question 9: Which cholinergic agonist is most appropriate for treating acute angle-
closure glaucoma due to its rapid miotic effect?
A. Bethanechol
B. Pilocarpine
C. Neostigmine
D. Donepezil
CORRECT ANSWER: B. Pilocarpine
Rationale: Pilocarpine is a direct-acting muscarinic agonist that causes pupillary
constriction (miosis) and ciliary muscle contraction, facilitating aqueous humor outflow
and reducing intraocular pressure in acute angle-closure glaucoma. Bethanechol
targets bladder/GI tract, neostigmine is an indirect cholinesterase inhibitor, and
donepezil is used for Alzheimer's disease.
, Question 10: Organophosphate poisoning is treated with pralidoxime (2-PAM)
primarily because it:
A. Blocks muscarinic receptors to reduce secretions
B. Reactivates acetylcholinesterase inhibited by organophosphates
C. Enhances renal excretion of the toxin
D. Stimulates nicotinic receptors to restore neuromuscular function
CORRECT ANSWER: B. Reactivates acetylcholinesterase inhibited by
organophosphates
Rationale: Organophosphates irreversibly phosphorylate acetylcholinesterase.
Pralidoxime is an oxime that nucleophilically attacks the phosphorylated enzyme,
regenerating active acetylcholinesterase if administered before "aging" occurs. Atropine
is co-administered to block excess muscarinic stimulation.
Question 11: Which calcium channel blocker is most selective for vascular smooth
muscle and is preferred for hypertension?
A. Verapamil
B. Diltiazem
C. Nifedipine
D. Bepridil
CORRECT ANSWER: C. Nifedipine
Rationale: Dihydropyridines like nifedipine exhibit high selectivity for L-type calcium
channels in vascular smooth muscle over cardiac tissue, causing potent vasodilation
with minimal negative inotropy. Verapamil and diltiazem have greater cardiac effects
and are used for arrhythmias or angina.
Question 12: The primary mechanism by which ACE inhibitors reduce blood
pressure is:
A. Blockade of angiotensin II type 1 (AT1) receptors
B. Inhibition of angiotensin-converting enzyme, reducing angiotensin II formation
C. Direct vasodilation via nitric oxide release
D. Increased renal excretion of sodium and water
CORRECT ANSWER: B. Inhibition of angiotensin-converting enzyme, reducing
angiotensin II formation
Rationale: ACE inhibitors (e.g., lisinopril) block conversion of angiotensin I to
angiotensin II, a potent vasoconstrictor and aldosterone stimulator. This reduces
vascular tone, blood volume, and cardiac remodeling. ARBs (option A) block the
receptor directly; diuretics cause option D.
Question 13: Which antiarrhythmic drug class is characterized by sodium channel
blockade with slow kinetics, prolonging the QRS complex?
